Lake Street Capital Initiates Coverage on InspireMD (NYSE:NSPR)

Investment analysts at Lake Street Capital assumed coverage on shares of InspireMD (NYSE:NSPR) in a research note issued on Wednesday,Benzinga reports. The firm set a “buy” rating and a $5.00 price target on the stock. Lake Street Capital’s price target suggests a potential upside of 61.81% from the company’s current price.

Several other research analysts have also recently issued reports on the stock. StockNews.com started coverage on shares of InspireMD in a report on Wednesday, December 4th. They issued a “sell” rating for the company. Piper Sandler reiterated an “overweight” rating and issued a $4.50 price target on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Price Performance

Shares of NYSE NSPR opened at $3.09 on Wednesday. The stock has a market cap of $80.60 million, a P/E ratio of -4.12 and a beta of 0.98. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.42. The firm has a 50-day moving average of $2.66 and a 200 day moving average of $2.68.

InspireMD (NYSE:NSPR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. The business had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same period in the previous year, the company earned ($0.15) earnings per share. Research analysts expect that InspireMD will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Parkman Healthcare Partners LLC bought a new stake in shares of InspireMD, Inc. (NYSE:NSPR) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned 0.42% of InspireMD at the end of the most recent quarter. 44.78% of the stock is currently owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.